Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02919111 · ClinicalTrials.gov registry record · Phase 2
Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients
A Phase 2 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 299
- Enrollment target
NCT02919111: Completed Phase 2 study, sponsored by University of California, San Francisco.
NCT02919111 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 299 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (125% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02919111, a Phase 2 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 299 participants
- Enrollment target
Study Summary
The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68-PSMA-11) in order to evaluate it's ability to detection prostate cancer in patients with high risk disease prior to prostatectomy.
Primary Outcome
Sensitivity is defined as the ratio of the proportion of the patients who have the condition of interest and whose test results are positive over the number who have the disease. Patients who have a positive node on imaging and on pathology will be considered a true-positive. Patients who have no nodes on imaging and pathology will be considered true-negatives. Patients with positive nodes on imaging and negative on pathology will be considered false positives and those with positive nodes on pa
Interventions
- DRUG Ga-68 labeled PSMA-11 PET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 299 participants |
| Start Date | 2016-09-23 |
| Est. Completion | 2019-12-31 |
| Phase | Phase 2 |
What the finished NCT02919111 record still lists
NCT02919111 is an interventional study that assigns participants to a tested intervention. The registered 299 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (125% higher).
The record links to 0 conditions, and to 1 intervention - of which Ga-68 labeled PSMA-11 PET is the first listed.
NCT02919111 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02919111 about?
NCT02919111 is a clinical study titled "Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients". The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68-PSMA-11) in order to evaluate it's ability to detection prostate cancer in patients with high risk disease prior to prostatectomy.
What is the current status of trial NCT02919111?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 299 participants. The study started on 2016-09-23. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT02919111?
The interventions under investigation include: Ga-68 labeled PSMA-11 PET (DRUG).
Who is sponsoring clinical trial NCT02919111?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02919111's enrollment target sits among peer trials
299 188th of 2000 higher than 1,813 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI